Gepants: targeting the CGRP pathway for migraine relief
Abstract
Background: Calcitonin gene-related peptide (CGRP) receptor antagonist (collectively known as gepant) have emerged as effective therapies for both acute migraine treatment and preventive management. Several new agents (atogepant, ubrogepant, rimegepant, and zavegepant) expand therapeutic options beyond traditional triptans and monoclonal antibodies. Objective: To summarize and critically evaluate the pharmacology, clinical efficacy, safety, and positioning of currently approved gepants for migraine treatment and prevention. Methods: A structured literature search was performed in PubMed/MEDLINE, Embase, Web of Science, Scopus, Cochrane Library, and ClinicalTrials.gov for studies published from 1998 to September 2025. Search terms included "gepant," "CGRP receptor antagonist," "atogepant," "ubrogepant," "rimegepant," "zavegepant," "pharmacokinetics," "efficacy," and "safety," combined with Boolean operators. Peer-reviewed clinical studies providing data on pharmacology, efficacy, or safety were included; case reports, conference abstracts, and non-English articles were excluded. Results: Four gepants are currently approved for clinical use. Atogepant is indicated solely for prevention, while ubrogepant and zavegepant are approved for acute treatment; rimegepant is approved for both indications. All agents exhibit favorable pharmacokinetic profiles, with oral or intranasal formulations enabling rapid onset and convenient dosing. Across randomized controlled trials, gepants…
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.